WO2001023414A3 - Immunologically significant herpes simplex virus antigens - Google Patents

Immunologically significant herpes simplex virus antigens Download PDF

Info

Publication number
WO2001023414A3
WO2001023414A3 PCT/US2000/026663 US0026663W WO0123414A3 WO 2001023414 A3 WO2001023414 A3 WO 2001023414A3 US 0026663 W US0026663 W US 0026663W WO 0123414 A3 WO0123414 A3 WO 0123414A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigens
hsv
herpes simplex
prevention
simplex virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/026663
Other languages
French (fr)
Other versions
WO2001023414B1 (en
WO2001023414A2 (en
Inventor
David M Koelle
Hongbo Chen
Lawrence Corey
Nancy Ann Hosken
Patrick Mcgowan
Steven P Fling
Christine M Posavad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Corixa Corp
Fred Hutchinson Cancer Center
Original Assignee
University of Washington
Corixa Corp
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00968457A priority Critical patent/EP1222281B1/en
Priority to NZ517959A priority patent/NZ517959A/en
Priority to CA2379623A priority patent/CA2379623C/en
Priority to HK02106470.4A priority patent/HK1044799A1/en
Priority to JP2001526564A priority patent/JP2003512305A/en
Priority to AU78364/00A priority patent/AU782676B2/en
Priority to KR1020027004169A priority patent/KR20020048944A/en
Priority to DE60031874T priority patent/DE60031874D1/en
Priority to BR0014408-8A priority patent/BR0014408A/en
Application filed by University of Washington, Corixa Corp, Fred Hutchinson Cancer Center filed Critical University of Washington
Publication of WO2001023414A2 publication Critical patent/WO2001023414A2/en
Publication of WO2001023414A3 publication Critical patent/WO2001023414A3/en
Publication of WO2001023414B1 publication Critical patent/WO2001023414B1/en
Priority to NO20021479A priority patent/NO20021479L/en
Anticipated expiration legal-status Critical
Priority to AU2005234654A priority patent/AU2005234654B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides HSV antigens that are useful for the prevention and treatment of HSV infection. Disclosed herein are epitopes confirmed to be recognised by T-cells derived from herpetic lesions. T-cells having specificity for antigens of the invention have demonstrated cytotoxic activity against cells loaded with virally-encoded peptide epitopes, and in many cases, against cells infected with HSV. The identification of immunogenic antigens responsible for T-cell specificity provides improved anti-viral therapeutic and prophylactic strategies. Compositions containing antigens or polynucleotides encoding antigens of the invention provide effectively targeted vaccines for prevention and treatment of HSV infection.
PCT/US2000/026663 1999-09-30 2000-09-28 Immunologically significant herpes simplex virus antigens Ceased WO2001023414A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
BR0014408-8A BR0014408A (en) 1999-09-30 2000-09-28 Immunologically significant herpes simplex virus antigens; and methods for identifying and using them
CA2379623A CA2379623C (en) 1999-09-30 2000-09-28 Immunologically significant herpes simplex virus antigens
HK02106470.4A HK1044799A1 (en) 1999-09-30 2000-09-28 Immunoligically significant herpes simplex virus antigens
JP2001526564A JP2003512305A (en) 1999-09-30 2000-09-28 Immunologically important herpes simplex virus antigen
AU78364/00A AU782676B2 (en) 1999-09-30 2000-09-28 Immunologically significant herpes simplex virus antigens
KR1020027004169A KR20020048944A (en) 1999-09-30 2000-09-28 Immunologically significant herpes simplex virus antigens and methods for identifying and using same
DE60031874T DE60031874D1 (en) 1999-09-30 2000-09-28 IMMUNOLOGICALLY RELEVANT ANTIGENS FROM HERPES SIMPLEXVIRUS
EP00968457A EP1222281B1 (en) 1999-09-30 2000-09-28 Immunoligically significant herpes simplex virus antigens
NZ517959A NZ517959A (en) 1999-09-30 2000-09-28 Pharmaceutical compositions comprising herpes simplex virus (HSV) proteins ICP0 or UL47 and a method producing immune cells with the proteins
NO20021479A NO20021479L (en) 1999-09-30 2002-03-25 Immunologically significant herpes simplex virus antigens and methods for identifying and using them
AU2005234654A AU2005234654B2 (en) 1999-09-30 2005-11-17 Immunologically significant herpes simplex virus antigens and methods for identifying and using same

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US15718199P 1999-09-30 1999-09-30
US60/157,181 1999-09-30
US20366000P 2000-05-12 2000-05-12
US60/203,660 2000-05-12
US21810400P 2000-07-13 2000-07-13
US60/218,104 2000-07-13

Publications (3)

Publication Number Publication Date
WO2001023414A2 WO2001023414A2 (en) 2001-04-05
WO2001023414A3 true WO2001023414A3 (en) 2001-11-08
WO2001023414B1 WO2001023414B1 (en) 2002-02-28

Family

ID=27387973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/026663 Ceased WO2001023414A2 (en) 1999-09-30 2000-09-28 Immunologically significant herpes simplex virus antigens

Country Status (16)

Country Link
US (2) US6413518B1 (en)
EP (1) EP1222281B1 (en)
JP (2) JP2003512305A (en)
KR (1) KR20020048944A (en)
CN (1) CN1376201A (en)
AT (1) ATE345389T1 (en)
AU (2) AU782676B2 (en)
BR (1) BR0014408A (en)
CA (1) CA2379623C (en)
DE (1) DE60031874D1 (en)
HK (1) HK1044799A1 (en)
NO (1) NO20021479L (en)
NZ (2) NZ531980A (en)
PL (1) PL355265A1 (en)
TR (1) TR200200838T2 (en)
WO (1) WO2001023414A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375952B1 (en) * 1998-08-07 2002-04-23 University Of Washington Immunological herpes simplex virus antigens and methods for use thereof
US6821519B2 (en) 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
ATE488249T1 (en) 2001-07-31 2010-12-15 Univ Washington IMMUNOLOGICALLY SIGNIFICANT HERPES SIMPLEX VIRUS ANTIGENS AND METHODS FOR THEIR USE
DK1523582T3 (en) 2002-07-18 2009-03-02 Univ Washington Rapid, efficient purification of HSV-specific T lymphocytes and HSV antigens identified thereby
CN1753687A (en) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Application of CPG oligonucleotide in the treatment of hepatitis C virus infection
CA2538794C (en) * 2003-09-12 2016-04-19 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
EP2253956A3 (en) * 2004-05-24 2011-07-06 Baylor Research Institute Immune response assessment method
ATE514775T1 (en) * 2006-02-08 2011-07-15 Illumina Cambridge Ltd END MODIFICATION TO PREVENT OVER-REPRESENTATION OF FRAGMENTS
CA2658484A1 (en) * 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
US20100166808A1 (en) * 2008-11-17 2010-07-01 Giovanni Marco Pauletti Method of Facilitating Intracellular Uptake or Transcellular Transport of Cargo Using Nanocarriers Containing Optimal Surface Densities of Integrin-Specific Ligands
US8460674B2 (en) 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2408812B1 (en) 2009-03-17 2015-12-16 CardioVax, LLC Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis and related proteins, peptides and compositions
US9044447B2 (en) 2009-04-03 2015-06-02 University Of Washington Antigenic peptide of HSV-2 and methods for using same
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
EP2305277A1 (en) * 2009-09-18 2011-04-06 Forskarpatent I Syd AB Use of tolerogenic dendritic cells in treatment and prevention of atherosclerosis
WO2011060329A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
RU2013126626A (en) 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер IMMUNOMODULATING METHODS AND SYSTEMS FOR TREATMENT AND / OR PREVENTION OF HYPERTENSIONS
CN103501806A (en) 2010-11-12 2014-01-08 赛达斯西奈医疗中心 Immunomodulatory methods and systems for treating and/or preventing aneurysms
JP6055776B2 (en) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド Vaccines against herpes simplex virus type 2: Compositions and methods for inducing an immune response
EA033467B1 (en) * 2011-01-31 2019-10-31 Univ Pennsylvania Nucleic acid molecule for inducing an immune response against herpes virus and use thereof
CA2889659C (en) * 2011-11-11 2023-03-14 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
HRP20181102T1 (en) 2012-05-16 2018-09-07 Immune Design Corp HSV-2 Vaccines
NZ726168A (en) * 2014-06-26 2022-05-27 Heidelberg Immunotherapeutics Gmbh Topical application for an anti-hsv antibody
EP3365009A4 (en) * 2015-10-22 2019-07-03 ModernaTX, Inc. Herpes simplex virus vaccine
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
RU2769474C2 (en) * 2017-01-20 2022-04-01 Атара Байотерапьютикс, Инк. Methods for treating multiple sclerosis using autologous t cells
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
WO2022036103A1 (en) * 2020-08-13 2022-02-17 Rootpath Genomics, Inc. Compositions and methods for antigen identification
US20240174986A1 (en) * 2021-03-29 2024-05-30 Rational Vaccines, Inc. Mutant herpesvirus and vaccine compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055145A1 (en) * 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
CA2088600C (en) 1990-08-02 1999-11-16 Rae L. Burke Herpes simplex virus vp16 vaccines
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
GB9325496D0 (en) 1993-12-14 1994-02-16 Smithkline Beecham Biolog Vaccines
ATE365808T1 (en) 1995-07-28 2007-07-15 Marie Curie Cancer Care TRANSPORT PROTEINS AND THEIR USES
CA2270282A1 (en) * 1996-11-04 1998-05-14 Smithkline Beecham Corporation Novel coding sequences from herpes simplex virus type-2
US6169175B1 (en) * 1997-08-06 2001-01-02 Centers For Disease Control And Prevention Preparation and use of recombinant influenza A virus M2 construct vaccines
JP2002506886A (en) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション Antitumor immunity enhancement

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998055145A1 (en) * 1997-06-02 1998-12-10 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL SEQUENCES 1 December 1992 (1992-12-01), MCGEOCH D.J.: "HSV2 ICP0 protein.", XP002161838 *
KOELLE D.M. ET AL.: "Recognition of herpes simplex virus type 2 tegument proteins by CD4 T-cells infiltrating human genital herpes lesions.", J. VIROL., vol. 72, no. 9, September 1998 (1998-09-01), pages 7476 - 7483, XP002161837 *
MANICKAN E. ET AL.: "Vaccination vith recombinant vaccinia viruses expressing ICP27 induces protective immunity against Herpes simplex virus through CD4+ Th1+ T-cells.", J. VIROL., vol. 69, no. 8, August 1995 (1995-08-01), pages 4711 - 4716, XP002161836 *
MCGEOCH D J ET AL: "COMPARATIVE SEQUENCE ANALYSIS OF THE LONG REPEAT REGIONS AND ADJOINING PARTS OF THE LONG UNIQUE REGIONS IN THE GENOMES OF HERPESSIMPLEX VIRUSES TYPES 1 AND 2", JOURNAL OF GENERAL VIROLOGY,GB,SOCIETY FOR GENERAL MICROBIOLOGY, READING, vol. 72, no. PART 12, 1 December 1991 (1991-12-01), pages 3057 - 3075, XP000406755, ISSN: 0022-1317 *

Also Published As

Publication number Publication date
BR0014408A (en) 2002-07-02
EP1222281B1 (en) 2006-11-15
HK1044799A1 (en) 2002-11-01
JP2012214478A (en) 2012-11-08
AU2005234654B2 (en) 2008-04-24
CA2379623C (en) 2014-09-09
CN1376201A (en) 2002-10-23
TR200200838T2 (en) 2002-06-21
AU2005234654A1 (en) 2005-12-15
NO20021479D0 (en) 2002-03-25
DE60031874D1 (en) 2006-12-28
EP1222281A2 (en) 2002-07-17
KR20020048944A (en) 2002-06-24
ATE345389T1 (en) 2006-12-15
WO2001023414B1 (en) 2002-02-28
AU7836400A (en) 2001-04-30
PL355265A1 (en) 2004-04-05
AU782676B2 (en) 2005-08-18
JP5602188B2 (en) 2014-10-08
NZ531980A (en) 2005-04-29
WO2001023414A2 (en) 2001-04-05
US6413518B1 (en) 2002-07-02
US6962709B2 (en) 2005-11-08
CA2379623A1 (en) 2001-04-05
US20020155122A1 (en) 2002-10-24
JP2003512305A (en) 2003-04-02
NZ517959A (en) 2004-05-28
NO20021479L (en) 2002-05-03

Similar Documents

Publication Publication Date Title
WO2001023414A3 (en) Immunologically significant herpes simplex virus antigens
WO2000008051A3 (en) Immunological herpes simplex virus antigens and methods for use thereof
WO2003011893A3 (en) Immunologically significant herpes simplex virus antigens and methods for using same
WO2004009021A3 (en) Rapid, efficient purification of hsv-specific t-lymphocytes and hsv antigens identified via same
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
WO2000023955A8 (en) Virus-like particles for the induction of autoantibodies
WO2003059385A3 (en) Hiv vaccine and method of use
WO2000061766A3 (en) Telomerase-specific cancer vaccine
HK1048136B (en) Herpes viruses for immune modulation
CA2245545A1 (en) Vaccines against varicella zoster virus gene 63 product
WO2000012122A3 (en) Low-molecular fragments of hyaluronic acid for the preparation of vaccines
WO2000034445A3 (en) Live attenuated venezuelan equine encephalitis vaccine
WO2003002528A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
WO2003017943A3 (en) Therapeutic compositions and methods for treating viral infection
WO2004039945A3 (en) Preventive and therapeutic aids vaccines
WO2000018430A3 (en) Live virus vaccines to protect primates from hiv-1 infection and disease
WO2003008410A8 (en) Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression
WO2004053094A3 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
EP1222928A3 (en) Pharmaceutical compositions for treating or preventing cancer, especially melanoma
WO2004003153A3 (en) Live replicating spumavirus vector
WO2001044288A3 (en) Toscana virus nucleoprotein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/242/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 78364/00

Country of ref document: AU

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 2379623

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 517959

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/A/2002/003233

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 008134804

Country of ref document: CN

Ref document number: 2002/00838

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1020027004169

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2001 526564

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000968457

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002 2002111567

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027004169

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000968457

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1020027004169

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 517959

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517959

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 78364/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000968457

Country of ref document: EP